Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(13)70566-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study.
Lancet Oncol
December 2022
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer.
Methods: In this population-based study, we analysed 135 847 children (aged 0-14 years) diagnosed during 2000-13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries.
Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Lancet Child Adolesc Health
August 2022
Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands.
Background: Adolescent and young adult patients with rhabdomyosarcoma often have poorer outcomes than do children. We aimed to compare the findings of adolescent and young adult patients with children enrolled in two prospective clinical protocols.
Methods: This retrospective observational analysis was based on data from the European paediatric Soft tissue sarcoma Study Group (EpSSG) rhabdomyosarcoma 2005 trial (phase 3 randomised trial for localised rhabdomyosarcoma, open from April, 2006, to December, 2016) and the EpSSG MTS 2008 protocol (prospective, observational, single-arm study for metastatic rhabdomyosarcoma, open from June, 2010, to December, 2016), which involved 108 centres from 14 different countries in total.
Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study.
Eur J Cancer Prev
January 2017
aClaudius Regaud Institute, IUCT-O, Tarn Cancer Registry bLEASP - UMR 1027 Inserm Toulouse III University, Toulouse cDepartment of Biostatistics, University Hospital of Lyon, Lyon dUniversity of Lyon 1 eCNRS, UMR 5558, Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department, Villeurbanne, France fCatalan Institute of Oncology, Girona gBasque Health Department, Basque Cancer Registry, Public Health Division of Gipuzkoa, Bilbao hCIBER of Epidemiology and Public Health (CIBERESP), Donostia-San Sebastián, Spain.
Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009).
View Article and Find Full Text PDFTrends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material.
Eur J Cancer Prev
January 2017
aRomagna Cancer Registry, Romagna Cancer Institute (IRST) IRCCS, Meldola, Forlì, Italy bNational Centre for Epidemiology, Surveillance and Health Promotion, ISS, Rome cDipartimento di Medicina Predittiva e per la Prevenzione, S.S.D. Epidemiologia Valutativa, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy dDepartment of Biostatistics, University Hospital of Lyon eUniversity of Lyon, Lyon fUniversity of Lyon 1 gCNRS UMR 5558, Biometrics and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department, Health-Biostatistics Group, Villeurbanne hDepartment of Non-communicable Diseases and Injuries, French Institute for Public Health Surveillance (Invs), Sainte-Maurice iDigestive Cancer Registry of Burgundy, CHU de Dijon jINSERM U 866, University of Burgundy, Dijon, France.
The aim of the SUDCAN collaborative study was to compare the net survival from 15 cancers diagnosed in 2000-2004 in six European Latin countries and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. This paper presents a detailed description of the data analyzed and quality indicators. Incident cases from Belgium, France, Italy, Portugal, Spain, and Switzerland were retrieved from 56 general or specialized population-based cancer registries that participated in the EUROCARE-5 database.
View Article and Find Full Text PDFSurvival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5.
Lancet Oncol
July 2016
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Background: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!